Physician profile
Bryan Ross
NPI 1508600834
$1,983.85
in general payments reported to CMS, 2019-2025
11 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $462 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $456.49 | 2024-2025 | Tryptyr, Precision7, Precision 1 |
| Biotissue Holdings INC. | $390.79 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $297.80 | 2024-2025 | Infuse, Miebo, Xiidra |
| Visioneering Technologies, INC. | $236.09 | 2025 | |
| Amgen INC. | $140.34 | 2024-2025 | Tepezza |
| Coopervision INC. | $115.68 | 2024-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Harrow Eye, LLC | $98.83 | 2025 | Vevye |
| Dompe US, INC. | $92.03 | 2024-2025 | Oxervate |
| Lkc Technologies, INC. | $85.86 | 2025 | |
| Oyster Point Pharma, INC. | $36.26 | 2024 | Ryzumvi, Tyrvaya |
| Sun Pharmaceutical Industries INC. | $33.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.